Olmesartan Medoxomil recalls
The FDA has published 3 recalls involving Olmesartan Medoxomil since 2019. The latest was reported on 2 Jun 2021. Most were for potency & assay. Ascend Laboratories has the most recalls in this group. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls3since 2019
Last 12 months0reported
Class I00% of total
Ongoing0latest 2 Jun 2021
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 2 67%Class III 1 33%
Why olmesartan medoxomil is recalled
Companies
By year
All olmesartan medoxomil recalls, newest first
3 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Olmesartan Medoxomil Tablets, USP, 20 mg recalled by Ascend LaboratoriesOlmesartan Medoxomil | Ascend Laboratories | Other | Nationwide |
| Drug | CLASS II | Olmesartan Medoxomil Tablets 20 mg recalled by Ascend LaboratoriesOlmesartan Medoxomil | Ascend Laboratories | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS II | Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 40 mg/25 mg recalled | Teva Pharmaceuticals USA | Potency & Assay | Nationwide |
Should you stop taking Olmesartan Medoxomil?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.